Glycoprotein 41 (gp41) – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Glycoprotein 41 (gp41) – Pipeline Review, H2 2017’, provides in depth analysis on Glycoprotein 41 (gp41) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Glycoprotein 41 (gp41) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Infectious Disease under development targeting Glycoprotein 41 (gp41).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.


The report provides a snapshot of the global therapeutic landscape for Glycoprotein 41 (gp41)

The report reviews Glycoprotein 41 (gp41) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Glycoprotein 41 (gp41) targeted therapeutics and enlists all their major and minor projects

The report assesses Glycoprotein 41 (gp41) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Glycoprotein 41 (gp41) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Glycoprotein 41 (gp41)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Glycoprotein 41 (gp41) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Amunix Operating Inc

Frontier Biotechnologies Inc

InnaVirVax SA

Longevity Biotech Inc

Mymetics Corp

Navigen Inc

Osel Inc

Pharis Biotec GmbH

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Glycoprotein 41 (gp41) - Overview 7

Glycoprotein 41 (gp41) - Therapeutics Development 8

Products under Development by Stage of Development 8

Products under Development by Therapy Area 9

Products under Development by Indication 10

Products under Development by Companies 11

Products under Development by Universities/Institutes 13

Glycoprotein 41 (gp41) - Therapeutics Assessment 15

Assessment by Mechanism of Action 15

Assessment by Route of Administration 16

Assessment by Molecule Type 18

Glycoprotein 41 (gp41) - Companies Involved in Therapeutics Development 20

Amunix Operating Inc 20

Frontier Biotechnologies Inc 20

InnaVirVax SA 21

Longevity Biotech Inc 21

Mymetics Corp 22

Navigen Inc 22

Osel Inc 23

Pharis Biotec GmbH 23

Glycoprotein 41 (gp41) - Drug Profiles 24

CPT-31 - Drug Profile 24

Product Description 24

Mechanism Of Action 24

R&D Progress 24

DS-007 - Drug Profile 25

Product Description 25

Mechanism Of Action 25

R&D Progress 25

Enfuvirtide-XTEN - Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

FB-006M - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

HIV-1 vaccine - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

LBT-5001 - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

Monoclonal Antibodies to Target GP120 and GP41 for HIV - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

MYMV-101 - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

MYMV-201 - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

Recombinant Peptides for HIV-1 - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

Recombinant Protein to Inhibit Glycoprotein 41 and Glycoprotein 120 for Infectious Disease - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

Small Molecules to Target GP120 and Gp41 for HIV-1 Infections - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

STOP-3S - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

Synthetic Peptide to Target gp41 for HIV Infection - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

Synthetic Peptides to Inhbit GP41 for HIV Infections - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

Synthetic Peptides to Inhibit GP120, GP41, Tat, Integrase and Protease for HIV-1 Infection - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

VAC-02 - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

VAC-3S - Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

VIR-576 - Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

Glycoprotein 41 (gp41) - Dormant Products 48

Glycoprotein 41 (gp41) - Discontinued Products 50

Glycoprotein 41 (gp41) - Product Development Milestones 51

Featured News & Press Releases 51

Sep 13, 2017: Mymetics to Present New Preclinical Data on Thermostable and Cold-Chain Independent Virosome based Vaccines 51

Oct 20, 2016: Dr. Michael Kay Presents Recent Data on Navigen’s HIV Entry Inhibitor, CPT31, at the 2016 HIVR4P meeting 51

Sep 19, 2016: Mymetics and Texas Biomedical Research Institute Continue Collaboration on HIV Vaccine Development 52

Aug 24, 2016: Navigen Awarded $500,000 Grant to Support Depot Formulation of its HIV Drug Candidate 53

Jun 06, 2016: Frontier Biotech Long-acting HIV-1 Fusion Inhibitor Albuvirtide Meets 48-Week Primary Objective: Interim Results of a Phase 3 Trial 53

May 20, 2016: InnaVirVax Obtained FDA Authorization for a Phase 2 Clinical Trial with VAC-3S in HIV Functional Cure in the US 54

Apr 11, 2016: Mymetics' HIV vaccine candidate confirms promise in preclinical study with Texas Biomed 55

Jul 30, 2015: Encouraging results of the first clinical study of the VAC-3S vaccine against HIV, for which DIAXONHIT develops a companion diagnostic 56

Apr 30, 2015: Texas Biomed receives NIH grant to study papillomavirus-based AIDS vaccine 57

Oct 28, 2014: Amunix and PolyPeptide Enter Into Partnership to Produce XTEN Peptide Conjugates for Evaluation by Third Parties for Pharmaceutical Therapeutics 58

Jul 23, 2014: Amunix and PolyPeptide Publish Multivalent Antiviral XTEN-Peptide Conjugates in vivo Studies in American Chemical Society's Journal "Bioconjugate Chemistry" 58

Dec 01, 2013: InnaVirVax Initiates Phase 2 Clinical Trial Evaluating VAC-3S, A Therapeutic Vaccine Used in Combination With Standard Antiretroviral Therapy in Treatment of HIV-Infection 59

Mar 05, 2013: InnaVirVax Presents Results From Phase I/IIa Clinical Study Of VAC-3S At CROI 2013 60

Feb 21, 2013: Mymetics Announces Publication Of Positive Phase I Study Results Of HIV-1 Vaccine In PLOS ONE 60

Nov 30, 2012: InnaVirVax's HIV Vaccine VAC-3S Achieves Primary End Point In Phase I/IIa Study 61

Appendix 62

Methodology 62

Coverage 62

Secondary Research 62

Primary Research 62

Expert Panel Validation 62

Contact Us 62

Disclaimer 63

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H2 2017 8

Number of Products under Development by Therapy Areas, H2 2017 9

Number of Products under Development by Indication, H2 2017 10

Number of Products under Development by Companies, H2 2017 11

Products under Development by Companies, H2 2017 12

Number of Products under Investigation by Universities/Institutes, H2 2017 13

Products under Investigation by Universities/Institutes, H2 2017 14

Number of Products by Stage and Mechanism of Actions, H2 2017 15

Number of Products by Stage and Route of Administration, H2 2017 17

Number of Products by Stage and Molecule Type, H2 2017 19

Pipeline by Amunix Operating Inc, H2 2017 20

Pipeline by Frontier Biotechnologies Inc, H2 2017 20

Pipeline by InnaVirVax SA, H2 2017 21

Pipeline by Longevity Biotech Inc, H2 2017 21

Pipeline by Mymetics Corp, H2 2017 22

Pipeline by Navigen Inc, H2 2017 22

Pipeline by Osel Inc, H2 2017 23

Pipeline by Pharis Biotec GmbH, H2 2017 23

Dormant Projects, H2 2017 48

Discontinued Products, H2 2017 50

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H2 2017 8

Number of Products by Stage and Mechanism of Actions, H2 2017 15

Number of Products by Routes of Administration, H2 2017 16

Number of Products by Stage and Routes of Administration, H2 2017 16

Number of Products by Molecule Types, H2 2017 18

Number of Products by Stage and Molecule Types, H2 2017 18


Discounts available for multiple purchases.
+44 20 7947 2745

Saved reports